PTM 001
Alternative Names: PTM-001Latest Information Update: 28 Mar 2024
At a glance
- Originator Emory University; University of Michigan
- Developer PTM Therapeutics
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Focal adhesion protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (Intraperitoneal, Injection)
- 31 Aug 2021 Phoenicis Therapeutics plans a phase II trial for Hidradenitis suppurativa (In adults, In eldrely) in September 2021 (NCT05020730) .
- 17 Feb 2021 PTM Therapeutics plans a clincial trial for Inflammatory bowel diseases, in 2022